The first and only immunotherapy product for advanced cancer, sipuleucel-T (Provenge), has not been widely used clinically since its launch 10 years ago, and has been largely eclipsed by two drugs ...

The efficacy and safety of degarelix, a GnRH receptor antagonist: A multicenter, randomized, maintenance dose-finding phase II study with Japanese prostate cancer patients. A phase I/II randomized ...

Combining sipuleucel-T and radium-223 improves progression-free survival among men with metastatic castration-resistant prostate cancer (mCRPC) who have bone predominant metastases, a randomized phase ...

Evaluators report that data on survival were not evaluable because group differences might have been caused by the circumstances of the subsequent therapies when reviewing the potential added benefit ...

Sipuleucel-T May Help Blacks More Median overall survival was 9.3 months longer for black versus white patients with metastatic castration-resistant prostate cancer. The following article is part of ...

SEAL BEACH, Calif.--(BUSINESS WIRE)--Dendreon Pharmaceuticals LLC, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, released results of a new retrospective ...

In September, the American Society for Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) released the first guideline on metastatic castration-resistant prostate cancer (mCRPC) since 2007, ...

Radium-223’s (Ra-223) low levels of alpha particle radiation induce double-strand DNA breaks, which leads to cell apoptosis. Sipuleucel-T (SipT), which is an immunotherapy manufactured from a ...

The two trials randomized patients 2:1 to receive either sipuleucel-T immunotherapy—autologous peripheral blood mononuclear cells loaded with a recombinant fusion protein comprising prostatic acid ...

Regarding Sipuleucel-T for use in prostate cancer, information submitted by the drug manufacturer provided better evidence on mortality. However, it is not possible to exactly estimate the extent of ...

Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier ...

Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. The German Institute ...